A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

Abstract Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. The same pathway is also activated in plexiform neurofi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sébastien Perreault, Valérie Larouche, Uri Tabori, Cynthia Hawkin, Sarah Lippé, Benjamin Ellezam, Jean-Claude Décarie, Yves Théoret, Marie-Élaine Métras, Serge Sultan, Édith Cantin, Marie-Ève Routhier, Maxime Caru, Geneviève Legault, Éric Bouffet, Lucie Lafay-Cousin, Juliette Hukin, Craig Erker, Nada Jabado
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-12-01
coleção:	BMC Cancer
Assuntos:	Trametinib Glioma Plexiform neurofibroma Neurofibromatosis type 1 BRAF MEK inhibitor
Acesso em linha:	https://doi.org/10.1186/s12885-019-6442-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!